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Mutations in the gene encoding ε-sarcoglycan (SG) cause myoclonus dystonia syndrome  
 
(MDS). However, the precise role of this protein in the brain is not known. To understand  
 
the role that ε-SG plays in the disease, we sought to identify interacting partners for the  
 
cytosolic domain of ε-SG. Using proteomics/mass spectrometric approaches, we  
 
identified Erk2p as a putative interactor for the cytosolic domain of ε-SG. 
 
In addition, we also identified a putative D-site on the cytosolic domain of ε-SG which  
 
fits the consensus sequence (K/R)2-3X1-6-(L/I)-X-(L/I). D-sites are normally present in  
 
MAPK kinases to facilitate specific docking between MAPKs and their activating MEKs. 
 
Interestingly, abnormal inactive and active forms of Erk2 levels have been observed in  
 
various neuropathological conditions like schizophrenia and obsessive compulsive  
 
disorder. Thus, the putative interaction between Erk2p and the cytosolic domain of ε-SG  
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1. Introduction  
 
1.1 The Dystrophin-glycoprotein Complex (DGC)  
 
The dystrophin-glycoprotein complex (DGC) is a large transmembrane complex critical 
 
for the integrity of striated muscle membranes (Rando T.A. et. al, 2001). This complex  
 
consists of dystrophin, the gene product found in the Duchenne Muscular Dystrophy  
 
locus, α and β dystroglycans, sarcospan, syntrophins, dystrobrevins and the  
 
sarcoglycans (Durbeej. M. et al, 2002). The DGC links the extracellular matrix to the  
 
cytoskeleton. In striated muscle, the N-terminus of dystrophin binds cytoskeletal F-actin  
 
while its carboxyl-terminus binds β-dystroglycan. The absence of dystrophin in  
 
patients leads to Duchenne muscular dystrophy. Dystrophin, dystrobrevins and the  
 
syntrophins are intracellular components of the DGC. The composition and organization  
 
of the DGC may differ in non-muscle tissue (Xiao J. et al 2003).   
 
1.2 The Sarcoglycans 
 
The sarcoglycans (SG) are N-glycosylated transmembrane proteins with a large extra- 
 
cellular domain containing a carboxyl-terminal cluster with several cysteine 
 
residues, a single transmembrane domain and a short intra-cellular (cytosolic) tail. 
 
There are six known types of sarcoglycans i.e. α, β, γ, δ, ε, and ζ-SG. All six  
 
sarcoglycans are expressed in striated muscle tissue while α-SG is absent in smooth  
 
muscle (Barresi R et al 2000, Straub V et al 1999, Wheeler M.T. et al 2002).  β, δ and ε- 
 
sarcoglycans are expressed in the brain, with ε-SG having the highest expression in the  
 
brain over β and δ-SG, while α-SG is not present in the brain. (Entrez Protein information  
 
database www.ncbi.nlm.nih.gov). Recently, ζ-SG was also found to be highly expressed  
 
in the brain (Shiga K. et al 2006). The sarcoglycans are part of the dystrophin  
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glycoprotein complex (DGC). They are known to stabilize the DGC (Hack A.A. et al  
 
2000). The molecular architecture of the sarcoglycans in relation to the DGC is as  
 
follows: δ-SG may be closely associated with dystroglycan, γ-SG linked to dystrophin, β,  
 
γ and δ-SG and particularly β and δ-SG tightly associated while α-SG is postulated to be  
 
less tightly linked to the complex (Hack A.A. et al 2000).  
 
It is also hypothesized that both α and ε-SG may function as independent modules for  
 
signaling considering the high sequence homology between the two proteins (McNally  
 
E.M. et al 1998). A model of the muscle dystrophin glycoprotein complex (Rando T.A. et  
 





1.3 Neuronal Dystrophin-glycoprotein Complex 
 
For comparison, the neuronal dystrophin glycoprotein is shown in the Figure 2. The  
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molecular architecture of the neuronal DGC is very similar to its muscle counterpart. The  
 
sarcoglycan complex is associated with dystroglycan while α-dystroglycan associates  
 
with neurexin in the neuronal DGC, agrin in glial DGC and laminin in vascular DGC  
 
(Culligan K. et al 2002). Dystrophin binds to dystrobrevin via helical leucine (L-H)  
 
heptads making up coiled-coil domain. Syntrophins recruit neuronal nitric oxide synthase  
 
(nNOS) as well as other nonestablished voltage-gated ion-channels and/or kinases (KIN)  
 
to the complex. Only β, ε , δ and ζ sarcoglycans are present in the brain and the protein  
 








1.4 Mutations in the Sarcoglycans Cause Diseases  
 
Mutations of α, β, γ and δ-sarcoglycans are associated with autosomal recessive limb- 
 
girdle muscular dystrophies (LGMD) (Hack A.A. et al 2000); in contrast, mutations in  
 
the ε-SG gene are associated with a disorder of the central nervous system, the  
 
myoclonus-dystonia syndrome (MDS) (Zimprich et al 2001, OMIM number #159900).  
 
MDS is an autosomal dominant disorder characterized by both myoclonic and dystonic  
 
muscle contractions such as writer’s cramp and associated with psychiatric  
 
manifestations such as obsessive compulsive disorder and panic attacks.   
 
1.5 Protein Interactors of Sarcoglycans and MAP Kinase 
 
The only protein interactor known to interact with sarcoglycan to date is filamin 2, a  
 
muscle specific protein. It was shown to interact with the cytosolic domain of γ-SG in  
 
muscle tissue and no other protein interactor for the cytosolic domain of ε-SG has been  
 
identified to date. The data presented herein shows that the cytosolic domain of ε-SG   
 
may bind Erk2p/Mapk1p, which is consistent with the presence of a putative MAPK- 
 
docking site or “D-site”. D-sites are found in MAPK kinases (MAPKKs or MEKs) to  
 
facilitate specific docking between MAPKs and their activating MEKs. The MAPK/ERK  
 
proteins are at the lower end of the signal transduction within a MAPK cascade module  
 
and are generally preceded by two other protein kinases. The MAPK/ERK proteins  
 
receive the signal in the form of an activating phosphorylation by a preceding protein  
 
kinase known as MAP/ERK kinase (MEK) or also called MAP kinase kinase (MAPKK).  
 
The MEK proteins are themselves substrates for yet another set of upstream protein  
 
kinases, the MEK kinases (MAPKKKs).The MEK kinases include the various Raf  
 
kinases activated by Ras protein, Mos kinase and the protein kinases MEKK1, MEKK2  
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and MEKK3. The MAP kinase (Mitogen Activated Protein Kinase) signaling pathway is  
 






1.6 Aims of the Project 
 
In order to elucidate the molecular pathogenesis of MDS, the function which ε-SG  
 
plays within the cellular context needs to be determined. The clue to that may lie in the  
 
proteins that interact with ε-SG. Hence, the project was performed with the following  
 
main objectives, i.e., (1) to identify putative interactor(s) for the cytosolic domain of ε- 
 
SG and (2) to confirm the interaction(s) via binding assays such as  
 
co-immunoprecipitaion experiments. Human ε-SG gene was cloned and sequenced and  
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the proteins interacting with its cytosolic domain isolated from solublized mouse brain  
 
lysates and identified using MALDI-TOF (Matrix Assisted Laser Desorption and  
 
Ionization Time of Flight) mass-spectrometry. Rabbit antibodies to ε-SG were also  
 
generated, characterized and used in co-immunoprecipitation experiments with mouse  
 







































2. Materials and Methods 
 
2.1 cDNAs- The following cDNA sequences were used in this study: SGCE/ε-SG from  
 
Homo sapiens (SGCE; GenBank/EBI accession number NM_003919). Erk2 from Mus  
 
musculus (Mapk1; GenBank/EBI accession number NM_001038663). 
 
2.2 Plasmids for Recombinant Protein Expression in Bacteria- Human expressed  
 
sequence tag (EST) clone I.D. CS0DI008YP01 encoding the full length sequence of ε-SG  
 
cDNA constructed by the IMAGE Consortium was obtained from MRC Geneservice  
 
(Cambridge, UK). Primers for sequencing ε-SG were designed and the sequence of that  
 
clone verified by PCR sequencing reaction using Big Dye version 3.1 (P.E. Biosystems,  
 
San Jose, California, USA). The sequencing primers are listed in Table 2. As shown in  
 
Table 1, EST clone CS0DI008YP01 encodes a full length human ε-SG cDNA and was  
 
cloned into pCMVSPORT6 vector. 
 
  The cytosolic domain of ε-SG was amplified by PCR using Expand High Fidelity PCR  
 
System from Roche (Basel, Switzerland); utilizing the above-mentioned EST clone as  
 
template and using primers P11 and P9 as listed in the list of primers in Table 2. The  
 
resulting PCR product was a blunt ended 300 b.p (base pairs) product with EcoRI and  
 
XhoI restriction sites added at its 5’ and 3’ end respectively. The product was gel purified  
 
using Qiagen (Qiagen GmbH, Germany), PCR purification kit and blunt end ligated first  
 
into pPCR-Script from Stratagene (Stratagene La Jolla, CA, USA). The ligation mix was  
 
used to transform electro-competent E.coli. The bacteria were then plated onto ampicillin  
 
Luria-Bertani (LB) agar plates for selection, with 4µl of 1M isopropyl-1-thio-β-D- 
 
galactopyranoside (IPTG) and 50ul of 40mg/ml X-gal. The resulting white colonies,  
 
supposed to contain the desired insert, were picked and plasmid preparations made. The  
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positive clones were again sequenced to check for any mutation that may have occurred  
 
during the PCR reaction. The confirmed clone was then amplified and the desired insert  
 
excised using EcoRI and XhoI and cloned in-frame into pGEX5X-1, creating a  
 
glutathione-S-transferase (GST) fused to the N-terminus of the ε-SG cytosolic domain.  
 
The resulting plasmid is named pBH 1 as shown in Table 1. The same approach was used  
 
to construct pBH 2, which is a GST fusion with the ε-SG extra-cellular (ECD) domain.  
 
Primers P12 and P13 were used in this case and the PCR product obtained was 800 Bp.  
 




2.3 Creation of ε-SG Deletion Constructs for D-site Characterization- A  
 




To create the following constructs, the Igκ secretory signal, a FLAG tag and a small part  
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of the N-terminal DNA sequence of ε-SG ECD were first fused together by designing  
 
primers P14 and P19. A plasmid, pSecTag (Invitrogen Inc. Carlsbad, CA, USA)  
 
containing the full sequence of Igκ secretory signal was used as template. The resulting  
 
PCR product using P14 and P19 was a 200 Bp product containing the full Igκ secretory  
 
signal, FLAG epitope and a portion of the ε-SG ECD sequence. Concurrently, the  
 
deletion constructs without the Igκ and FLAG epitope were made using P15 and the  
 
respective primers P16 (for cloning up to the TM region); P17 (for cloning up to D-site  
 
region); and P18 (for cloning full length cDNA).  
 
The EST clone containing the sequenced full length ε-SG was used as template. These  
 
PCR products were then gel purified. To fuse the Igκ and FLAG to the N-terminal of ε- 
 
SG, the PCR product containing the Igκ , FLAG and a small portion of ε-SG ECD was  
 
mixed together with the PCR products of the deletions and another round of PCR was  
 
performed using P14 and the respective primers P16, 17 and 18 to obtain the final  
 
constructs as shown in Figure 5. The sequences of all the constructs were checked by  
 
sequencing. All three constructs were cloned into the mammalian expression vector  
 
















2.4 Creation of ε-SG Constructs with C-terminal HA tag, Endogenous Signal  
 
Peptide and either the First or the First and Second Initiation Methionine- A  
 




 To ensure that there are no additional methionines upstream of the first one in the  
 
published ε-SG cDNA, human genomic DNA sequences upstream of ε-SG were obtained  
 
from the Ensemble database (www.ensembl.org) and upon analysis, it was found that  
 
there are two in-frame stop codons and no additional start codons upsteam of the very  
 
first methionine in the ε-SG cDNA. Sequences of ε-SG from different species i.e. mouse,  
 
rat and human were obtained and aligned and it was discovered that the -22 bases  
 
upstream from the first ATG of ε-SG are almost similar. Primers P20 and P21 were  
 
designed based on these sequences and designated as primers with endogenous Kozak  
 
(Kozak M 1987) as shown in Table 2. P21 has the first ATG of ε-SG cDNA mutated to  
 
TTG. This was to determine which methionine was used in the translation of ε-SG. If  
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upon mutation of the first methionine, ε-SG is not expressed, then it would imply that the  
 
first methionine is mandatory for the expression of ε-SG. This lead to the creation of  
 
pBH6 and 7 (Plasmid Table 1) containing full length ε-SG with -22 upstream sequences  
 
of the ε-SG cDNA (endogenous Kozak) and a C-terminal hemagglutinin (HA) epitope  
 
tag. pBH 7 has the first ATG of ε-SG cDNA mutated to TTG, reasons stated above.  To  
 
create pBH6, primers P20 and P22 were used and for pBH7, primers P21 and P22 were  
 
used in PCR and the template for both cases was the EST clone containing full length ε- 
 
SG. P22 is a reverse primer with a XhoI restriction site and HA epitope tag engineered  
 
into it. For pBH8 and 9, the Kozak sequence used was not the endogenous one but a well  
 
established consensus sequence (established Kozak in Plasmid Table 1). Both these  
 
constructs have a FLAG epitope fused to the N-terminus. pBH8 starts from the first ATG  
 
of ε-SG while pBH9 starts from the second ATG of ε-SG. To create pBH8, primers P23  
 
and P9 were used; while P24 and P9 were used to create pBH9, again using the EST  
 
clone containing full length ε-SG cDNA as a template. All constructs were cloned into  
 
pcDNA3, sequences were confirmed by sequencing reactions. 
 
2.5 Recombinant Protein Expression in E.coli- pBH 1 and 2 are pGEX based vectors,  
 
the cloned recombinant GST fusion cDNA under the control of a strong and regulatable  
 
tac promoter (Ptac), a hybrid of the lac and trp promoters. As shown in Annex A, pGEX  
 
vectors encode a lac Iq repressor. The superscript ‘q’ signifies a mutation in the promoter  
 
of Lac I gene resulting in higher expression of Lac I repressor protein due to increased  
 
transcription. In the absence of an inducer, the Lac I repressor binds to the operator  
 
region adjacent to Ptac, resulting in the repression of downstream gene expression. In the  
 
presence of the inducer IPTG, the Lac I repressor dissociates from the operator region  
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due to conformational changes upon binding to IPTG and as a result, expression of the  
 
downstream recombinant gene is facilitated. pBH 1 and 2 were transformed into electro- 
 
competent, protease deficient BL21 CodonPlus (DE3) E.coli (Stratagene La Jolla, CA,  
 
USA) via electrophoration and plated on (LB) agar containing ampicillin and  
 
chloramphenicol for selection. Ampicillin was used to select for the GST vectors with the  
 
desired gene pBH1 and 2, while chloramphenicol was used to select for the pACYC  
 
based plasmid which encodes chloramphenicol acetyl transferase, the gene which confers  
 
chloramphenicol resistance. Genes that encode rare bacterial tRNAs are also present in  
 
the pACYC plasmid. Efficient production of heterologous proteins in E.coli is frequently  
 
limited by the rarity of certain tRNAs that are abundant in the organisms from which the  
 
heterologous proteins are derived. Forced high levels of heterologous proteins can deplete  
 
the pool of rare tRNAs in E.coli and stall translation. BL21 CodonPlus strains are  
 
engineered to contain extra copies of genes that encode the tRNAs that most frequently  
 
limit heterologous protein translation in E.coli, thus allowing high level expression of  
 
many heterologous recombinant proteins in BL21 CodonPlus cells that are often poorly  
 
expressed in conventional BL21 cells. Single colonies were picked and inoculated into  
 
liquid LB media containing the two antibiotics and cultured overnight at 37ºC. The  
 
following day, 10ml of the overnight cultures were used to inoculate 1L of liquid LB  
 
media containing the two antibiotics. The optical density of the bacterial cultures was  
 
monitored until they reached an absorbance of 0.6 at a wavelength of 600nm. A sample  
 
of this culture was taken and labeled as ‘uninduced’. IPTG was then added to the culture  
 
to a final concentration of 1mM for the induction of protein production and the  
 
temperature was shifted to 30ºC. The cultures were induced for 3hrs 30mins and a sample  
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of this culture was taken and labeled as ‘induced’. The ‘uninduced’ and ‘induced’  
 
samples were boiled in Laemmli sample buffer at 95ºC for 5 mins and analysed using  
 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie  
 
Blue staining to check for expression levels of the recombinant proteins. The remainder  
 
of the bacteria was harvested by centrifugation and the pellets stored at -80 ºC.  
 
2.6 An attempt to produce soluble GST-ε-SG-ECD- In an attempt to produce soluble 
 
GST- ε-SG-ECD, the Rosetta-gami strain of E.coli, (Novagen, Merck Biosciences,  
 
Germany) was used. The Rosetta-gami strain has mutations in both the thioredoxin  
 
reductase (trxB) and glutathione reductase (gor) genes, which greatly enhances  
 
disulphide bond formation in the cytoplasm (Besette P.H. et al 1999). The Rosetta-gami  
 
strain was transformed using the plasmid harbouring GST-ε-SG ECD and protein  
 
production was induced as described above. To check if the expressed protein was  
 
soluble, a sample of the bacteria was obtained and subjected to sonication using a fine tip  
 
sonicator. The sonicated sample was then spun and the pellet labeled ‘post sonication  
 
pellet’ (PSP). The uninduced, PSP and soluble fraction were analysed using SDS-PAGE  
 
and Coomassie staining.  
 
2.7 Purification of GST fusion protein in E.coli- The GST fusion protein expressed in  
 
E.coli was purified using Glutathione Sepharose 4B beads (Amersham/Pharmacia  
 
Biotech, Uppsala, Sweden). All procedures were done at 4ºC. Sonication buffer,  
 
consisting of phosphate buffered saline (PBS) high salt (0.5M NaCl), 1% Triton-X 100,  
 
CompleteTM protease inhibitor cocktail (Roche) and 1mM DTT were added to bacterial  
 
pellets. The mixture was then sonicated using a Misonix ultrasonicator (Misonix Inc, NY,  
 
USA), until a change in turbidity of the mixture was observed. The sonicated mixture was  
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centrifuged for 30 min using SS34 rotor and the resulting supernatant incubated with  
 
glutathione sepharose beads for 1hr 30min. After incubation, the glutathione beads were  
 
collected by mild centrifugation (300 x g) and washed extensively with sonication buffer.  
 
After the last wash, Laemmli sample buffer was added directly to the beads and boiled  
 
for 5mins at 95 ºC. The purified proteins were analysed by SDS-PAGE and Coomassie  
 
staining.   
 
2.8 Cleavage of ε-SG cytosolic domain from GST- When expressed from pGEX5X-1,  
 
the GST moiety can be removed from the fusion protein by subjecting it to Factor Xa  
 
(FXa) (Novagen) protease cleavage (Figure 1). GST- ε-SG Cyt was purified from  
 
bacteria as stated above using glutathione sepharose beads and the same amount of  
 
recombinant protein purified on beads subjected to increasing amount of FXa for  
 
cleavage. The cleavage reaction was done in FXa Cleavage/Capture Buffer (50mMTris- 
 
HCl, pH8.0, 100mM NaCl, 50mM CaCl2) at room temperature (R.T.) for 4hrs. A SDS- 
 
PAGE gel was run and Coomassie stained to analyze the efficiency of the cleavage.  
 
2.9 GST Interaction Assay with Soluble Mouse Brain Lysates- GST only as control  
 
and GST-ε-SG-Cyt were bacterially expressed and purified using glutathione beads.  
 
Adult mice were sacrificed, decapitated and brains extracted. The brains were  
 
homogenized in PBS and CompleteTM (Roche) protease inhibitor cocktail added, using a  
 
Dounce homogenizer. Tween 20 was added to a final concentration of 0.1% to the crude  
 
lysate and incubated at 4ºC for 45 minutes. The lysate was first centrifuged at 700 x g for  
 
10 min to remove unbroken cell debris, the supernatant collected and centrifuged at  
 
16000 x g for half an hour. The supernatant of the second centrifugation was carefully  
 
collected and used to incubate with GST and GST-ε-SG-Cyt coupled to glutathione beads  
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overnight at 4ºC. The following day, the beads were washed extensively with lysis buffer  
 
(Tween 0.1% PBS). The final two washes were with FXa Cleavage/Capture Buffer and  
 
the purified protein complex was subjected to the appropriate units of FXa for cleavage at  
 
room temperature for 7hrs. Contaminating FXa was removed using Xarrest agarose and  
 
the purified protein complex subjected to acetone precipitation. Laemmli sample buffer  
 
was added to the precipitated samples for SDS-PAGE (10% acrylamide gel) using a long  
 
gel for improved resolution. Due to its sensitivity, the imidazole-sodium dodecyl  
 
sulphate-zinc reverse staining method (Fernandez-Patron C. et al 1992) was used to  
 
detect protein interactors of ε-SG-Cyt (see next section).   
 
2.10 The Imidazole-sodium Dodecyl Sulphate-zinc Reverse (Negative) Stain  
 
Method- While Coomassie blue stains the protein itself and also fixes the protein within  
 
the gel matrix in the process, the imidazole sodium dodecyl sulphate (SDS) zinc method  
 
“negatively” stains the gel, i.e., it produces a semiopaque background on the gel surface  
 
while the proteins are shown up as transparent bands (Ortiz M.L. et al 1992). The  
 
disadvantages of using Coomassie blue staining over the imidazole SDS zinc method are  
 
twofold. Firstly, Coomassie blue staining is less sensitive than the imidazole SDS zinc  
 
method. Coomassie staining can detect proteins only in the microgram range while the  
 
imidazole SDS zinc stain is able to detect proteins down to nanogram levels. Secondly,  
 
Coomassie staining involves irreversible fixing of the proteins to the polyacrylamide  
 
matrix. During this fixation process by acetic acid and methanol, protein precipitation  
 
may occur and thus require prolonged digestion times (18-24hrs) and several extraction  
 
steps for optimal peptide recovery for mass spectrometry analysis (Castellanos-Serra L. et  
 
al 1999). The imidazole SDS zinc staining method on the other hand, fixes the protein  
 
 16 
reversibly to the polyacrylamide gel matrix. After the band(s) of interest is excised, a zinc  
 
chelating agent like glycine, which does not interfere with microsequencing analysis, is  
 
used in the destaining solution. Under these fully reversible fixative conditions, proteins  
 
can be rapidly eluted from the acrylamide gel microparticles with a 90-98% recovery  
 
(Castellanos-Serra L.R  et al 1996, 1997). The imidazole SDS zinc staining protocol used  
 
here was as follows. After SDS-PAGE, the acrylamide gel was rinsed in distilled water  
 
for 30 seconds. The water was poured off and the gel incubated in 0.2M imidazole  
 
solution with 0.1% SDS for 15 mins, after which the solution was discarded and the gel  
 
incubated with 0.2M zinc (II) sulphate solution until the gel background became deep  
 
white. This process occurs in about 30 secs.  The zinc staining was stopped by rinsing the  
 
gel with abundant distilled water. Care was taken not to overstain the gel. The staining  
 
process was monitored during development by placing the gel over a black surface. The  
 
bands of interest were excised with a clean scalpel and placed carefully in Eppendorf  
 
tubes. Destaining solution (50mM Tris-Hcl pH8.3, 0.3M glycine) was added until the gel  
 
slices became transparent. The glycine acts as a chelating agent that will remove zinc  
 
ions from the matrix. After destaining, the gel slices were washed several times with  
 
distilled water and sent for mass spectrometry analysis.  
 
2.11 Identification of Proteins by Mass Spectrometry- SDS-polyacrylamide gel slices  
 
containing protein bands of interest were destained as described above, reduced,  
 
alkylated and then in-gel digested with trypsin as described (Shevchenko et al 1996). The  
 
digested peptides were analyzed on a matrix assisted laser desorption and ionisation  
 
quadrupole/time-of-flight (MALDI-TOF) mass spectrometer (QSTAR, PESciex)  
 
equipped with a nanoelectrospray ion source. Protein identities were revealed by  
 
 17 
searching sequence data bases with peptide sequence tags generated by tandem mass  
 
spectrometry (Wilm M et al 1996, Mann M et al 1994).    
 
2.12 GST Pull-down Assay Between the Cytosolic Domain of ε-SG and In vitro- 
 
translated Erk2-HA- GST-ε-SG-Cyt was produced bacterially and purified using  
 
glutathione sepharose beads as described above. Erk2-HA was in vitro-translated as  
 
described in section 2.20 using TnT Quick Coupled Transcription/Translation  
 
Systems without the addition of canine microsomal membranes (CMM). Briefly, this  
 
system consists of rabbit reticulocyte lysate, RNA polymerase, nucleotides, salts and  
 
Recombinant Ribonuclease Inhibitor and is available in two configurations for  
 
transcription and translation of genes cloned downstream from either a T7 or an SP6  
 
promoter. In this case, the T7 promoter was used. The in vitro-translated Erk2-HA was  
 
then incubated overnight at 4°C with the purified GST-ε-SG-Cyt in PBS, 0.1% Tween-20  
 
and protease inhibitor cocktail. GST alone coupled to glutathione sepharose beads was  
 
used as a negative control. The following day, the beads were washed extensively with  
 
PBS, 0.1% Tween-20. The last two washes were with Factor Xa Capture/Cleavage buffer  
 
and appropriate amounts of Factor Xa were then added to the mixture to cleave the GST  
 
from the recombinant protein. The beads containing the coupled GST were spun down  
 
and the supernatant subjected to acetone precipitation. Laemmli sample buffer was added  
 
to the precipitated samples and Erk2-HA and the cytosolic domain of ε-SG detected by  
 
Western blot. Rat anti-HA was used for the detection of Erk-2-HA.   
 
 
2.13 Western Blot- For Western blot, Immobilin-P membranes (Millipore Bedford, MA,  
 




2.14 Antibodies- Mouse M2 anti-FLAG monoclonal antibodies and rabbit anti-FLAG  
 
antibodies were purchased from Sigma Aldrich Inc (St. Louis, MO, USA). Rat anti-HA  
 
was from Roche while mouse anti-Erk2 was from Cell Signaling Tech. Inc (Danvers,  
 
MA, USA). Antibodies against the cytosolic domain of ε-SG were made commercially by  
 
providing Biogenes (Germany) with the purified cytosolic domain as antigen for injection  
 
into rabbits.  
 
2.15 Characterization of Antibody Specific to Cytosolic Domain of ε-SG- Two  
 
criteria were used to establish the specificity of the antibody for the cytosolic domain of  
 
ε-SG. First, recognition in Western blots of crude bacterial lysates containing the protein  
 
of interest of a specific band of the correct molecular weight and second, competition  
 
with increasing amount of soluble antigen . Serum from two different rabbits, labeled  
 
rabbit 5956 and 5955 were obtained and preliminary results showed that the antibody  
 
from rabbit 5955 was cleaner and more specific. Hence, serum from rabbit 5955 was used  
 
in all experiments. A titration experiment was initially performed to determine a 1:2000  
 
dilution as optimal for Western blot. Crude bacteria lysates containing GST only, GST- ε- 
 
SG ECD and GST-ε-SG Cyt were boiled directly in Laemmli sample buffer, loaded onto  
 
PAGE gel and transferred onto PVDF membrane. To further demonstrate the specificity  
 
of the rabbit antibody against ε-SG-Cyt, a competition assay experiment was performed.  
 
Increasing amounts (0µg, 5µg, 10µg, 50µg and 100µg) of purified GST-ε-SG-Cyt and  
 
GST alone were incubated at room temperature (RT) for 1hr 30mins in PBS with the  
 
appropriate amount of rabbit anti-ε-SG-Cyt antibody (1:2000 dilution). After incubation,  
 
the antibody was used to probe Western blots with total mouse brain lysates. Human  
 
brain was not used due to the scarcity and difficulty in obtaining the samples. If the  
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antibody is specific, increasing amount of the antigen but not GST alone will out- 
 
compete the signal on the Western blot; whereas a redundant protein like GST will not  
 
out-compete the signal.    
 
2.16 Comparison of ε-SG in Mouse and Human Brain- To examine the difference of  
 
ε-SG in mouse and human brain, a sample of human cortex, obtained at autopsy of a  
 
person without any neurological disorders (Department of Pathology, University of Bern,  
 
according to the local procedures and laws) and mouse brain from in vivo Model System  
 
(IVMS) facility, Biological Resource Center (BRC), Biopolis. The samples were  
 
homogenized and 100µg of total protein was fractionated by SDS-PAGE and transferred  
 
onto PVDF membranes for Western blot using rabbit anti- ε-SG Cyt to detect presence of  
 
ε-SG in the samples.    
 
2.17 Immunoprecipitation Using Soluble Mouse Brain Lysates- Immunoprecipitation  
 
(IP) experiment was performed on soluble mouse brain lysates using different types of  
 
detergents, including 0.1%Tween in PBS, 1%Triton-X100 with 0.1% SDS in PBS, 1%  
 
Digitonin in PBS and 1% Sarkosyl in PBS. Mouse brains were homogenized in PBS  
 
using a Dounce homogenizer with CompleteTM  protease inhibitor cocktail added. The  
 
respective detergents were added from stock solutions to their final concentration to the  
 
mouse brain homogenate. The lysate was then incubated at 4ºC for 45mins. Differential  
 
centrifugation was performed on the brain homogenate as described above: first spin at  
 
700 x g for 10 minutes to remove unbroken cell debris, the supernatant collected and  
 
centrifuged at 16000 x g for half an hour and the supernatant aliquoted and used for IP.  
 
The lysates were first incubated with protein-G agarose at 4ºC for 1 hr 30 min to facilitate  
 
pre-clearing of non-specific binding. For the negative controls, non-specific mouse IgG (5  
 
µg) was added to the soluble brain lysate and in a separate sample 5 µg of mouse anti- 
 20 
 
Erk2p monoclonal antibody was used. The soluble mouse brain lysate and the antibodies  
 
were incubated at 4ºC overnight. The following day, Protein-G agarose was added to the  
 
samples and incubated at 4ºC for an additional 2hrs. The protein-G agarose was then  
 
pelleted by mild centrifugation (300 x g) and washed extensively with the respective  
 
binding buffers containing the respective detergents. The samples were boiled in  
 
Laemmli sample buffer and subjected to SDS-PAGE gel and Western blot analysis. To  
 
detect binding of ε-SG to Erk2p, the rabbit anti-ε-SG from Biogenes was used.   
 
2.18 Immunoprecipitation from Cos-1 Cells Transfected with Igκ Deletion  
 
Constructs- An IP experiment was performed with Cos-1 lysates, in the hope that the IP  
 
would concentrate the weakly expressed constructs. For the IP, all procedures were done  
 
at 4ºC. Transfected Cos-1 cells expressing the FLAG-ε-SG deletion constructs were  
 
scraped off from tissue culture plates, resuspended in PBS and subjected to mild  
 
sonication. Tween-20 was added to the sonicated mixture to a final concentration of 0.1%.  
 
The lysates were then incubated at 4ºC for 45 mins and centrifuged at 16,000 x g for 30  
 
mins. Anti-FLAG M2 coupled to agarose beads (Sigma Aldrich Inc.) was added to the  
 
supernatant and incubated for 2 hrs at 4ºC. The beads were harvested and washed 5 times  
 
with PBS, 0.1% Tween-20. The beads were then boiled in Laemmli sample buffer  
 
without β-mecaptoethanol or DTT. This was recommended by the manufacturer to  
 
prevent the dissociation of the heavy and light chain of the immobilized M2 antibody. A  
 








2.19 Immunoprecipitation of In vitro-translated Full length ε-SG-HA and Erk2- 
 
FLAG- pBH7, encoding full length ε-SG with endogenous Kozak and a C-terminal HA  
 
tag was subjected to in vitro-transcription/translation as described above, except that  
 
optimal amounts of canine microsomal membranes (CMM) (Promega Inc.,USA) were  
 
added. Erk2-FLAG was also in vitro-translated, but in the absence of CMM.  
 
Soluble mouse brain extracts were prepared as described above. The supernatant of the  
 
16’000 x g was used for this experiment and the brain extracts were prepared in PBS with  
 
protease inhibitor cocktail and Tween-20 0.1% added. The total protein content of the  
 
brain lysate was quantified using Bradford assay/reagent. 
 
For negative control, N-terminal FLAG-ZO2 was used. FLAG-ZO2 is cloned in pcDNA3  
 
downstream of T7 promoter. (FLAG-ZO2 pcDNA3 was a generous gift from D.C.Y.  
 
Phua). The protein was also expressed by in vitro-transcription/translation without CMM.  
 
Thus the samples for this set of experiment were as followed: 
 
1: Erk2-FLAG + Endogenous Kozak Full Length ε-SG + Soluble mouse  
                                                                                            brain lysate 150µg 
 
2: Erk2-FLAG + Endogenous Kozak Full Length ε-SG Only 
 
3: ZO2-FLAG + Endogenous Kozak Full Length ε-SG + Soluble mouse  
                                                                                            brain lysate 150µg 
 
4: Erk2-FLAG + Endogenous Kozak Full Length ε-SG + BSA 150µg 
 
If binding of Erk2 to ε-SG required a third party present in the mouse brain lysate,  
 
binding will only be detected in Sample 1. BSA was included as a redundant protein for  
 
negative control.  
 
The above combinations were incubated at 4ºC overnight in PBS, 0.1% Tween-20 and  
 
protease inhibitor cocktail. The following day, mouse monoclonal anti-FLAG M2  
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antibodies coupled to beads were added to the mixtures and incubated for another 2 hrs.  
 
The beads were then extensively washed with PBS, 0.1% Tween-20. Laemmli sample  
 
buffer without DTT or β-mecaptoethanol were added directly to the beads and boiled to  
 
elute the bound products without dissociation of the antibodies from the beads. DTT was  
 
then added to 100mM to the samples analyzed by SDS-PAGE and Western blot using rat  
 
anti-HA and rabbit anti-FLAG antibodies.    
 
2.20 In vitro-transcription/translation of ε-SG Constructs- TnT Quick Coupled  
 
Transcription/Translation Systems (Promega Inc.) was used for in vitro- 
 
transcription/translation of ε-SG constructs. This system consists of rabbit reticulocyte  
 
lysate, RNA polymerase, nucleotides, salts and Recombinant Ribonuclease Inhibitor and  
 
is available in two configurations for transcription and translation of genes cloned  
 
downstream from either a T7 or an SP6 promoter. In this case, the T7 promoter was used.  
 
In addition, since ε-SG is a transmembrane protein, canine pancreatic microsomal  
 
membranes (CMM) were added to the transcription/translation mixture. For the ε-SG  
 
constructs, addition of CMM was mandatory as no protein was expressed in the absence  
 
of CMM. The optimal amount of CMM used in the reaction had to be titrated since  
 
increasing the amount of membranes in the reaction increases the proportion of  
 
polypeptides that are processed but reduces the total amount of polypeptides synthesized.  
 
In a typical 25µl reaction mixture, the following reagents were added: 
 
 
TnT Quick Coupled Master Mix             20µl 
Methionine (1mM)                                  0.5µl 
Plasmid DNA                                          2.0µl 
CMM (increasing amounts for titration) 0.3µl/0.6µl/1.8µl 
Nuclease free water added to                  25µl. 
 
The reaction mixtures were incubated at 30ºC for 1 hr 30 min. Erk2-HA and Erk2-FLAG  
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were also in vitro-translated in the absence of CMM and used as positive controls in this  
 
set of experiments. Erk2-HA and Erk2-FLAG constructs (a generous gift from B. McCaw)  
 
were in pXJ40 vector (Xiao J.H. et al 1991), cloned downstream of the T7 promoter. For  
 
the negative control, empty pcDNA3 was used and 1.8µl of CMM added to the reaction.  
 
5µl of each reaction taken and analyzed by SDS-PAGE and Western blot using rat anti- 
 




2.21 Detection of Endogenous ε-SG in Cell Lines-293T and Cos-1 cells were grown in  
 
Dulbecco's Modification of Eagle's Medium (DMEM) complete with fetal calf serum  
 
(FCS), to approximately 90% confluency on tissue culture plates. The cells were handled  
 
in a sterile Class 2 Biohazard tissue culture hood using aseptic techniques to prevent  
 
contamination.  The cells were then scraped off the plate using a rubber policeman,  
 
resuspended in PBS, subjected to mild sonication and then protease inhibitor cocktail and  
 
Tween 20 added to a final concentration of 0.1%. The resulting mixture was incubated at  
 
4ºC for 45 mins, centrifuged at 16,000 x g in a microcentrifuge for 30 mins and both  
 
pellet and supernatant analyzed by SDS-PAGE and Western blot using the Biogenes  
 
antibody to detect endogenous ε-SG. The proteins in the supernatant were first  
 
concentrated by acetone precipitation and then boiled in sample buffer. Alternatively, cell  
 
suspensions were directly boiled in Laemmli sample buffer to obtain total cell lysates. 
 
2.22 Transfection of Deletion Constructs in Mammalian Cell Lines- Lipofectamine  
 
PLUSTM  Reagent (Life Technologies Inc.), a liposome based transfection system, was  
 
used in all mammalian cell transfection experiments done. Transfections were done under  
 
serum free conditions. Cells were counted and seeded to the appropriate density one day  
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before transfection so that they reached approximately 90% confluency on the day of  
 
transfection. The desired plasmid were pre-complexed with the PLUS reagent and added  
 
to the desired volume of transfection reagent (OPTI-MEM, Invitrogen). The mixture was  
 
incubated at room-temperature for 15 mins. Lipofectamine reagent was diluted with  
 
OPTI-MEM and added to the pre-complexed DNA. The resulting mixture was incubated  
 
for an additional 15 mins. While liposome-DNA complexes formed, the cells were rinsed  
 
twice with serum-free DMEM to remove serum before transfection. After the last rinse,  
 
OPTI-MEM was added, followed by the DNA complexes. The cells were incubated at  
 
37ºC in a CO2 incubator for 3hrs. DMEM was then added to the cells and fetal calf serum  
 
(FCS) supplemented to a final concentration of 10%. The cells were incubated overnight  
 
and the media changed the next day. Cells were then incubated for an additional day  
 
























3. Results  
 
3.1 Generation of antibodies to ε-SG - In order to generate antibodies to ε-SG, the  
 
cytosolic (Cyt) and the extracellular domains (ECD) of ε-SG were selected as antigens  
 
for injection into rabbits. The ECD and the cytosolic regions were expressed as GST  
 
fusion proteins in protease deficient BL21 bacteria. The whole protein was not used  
 
because expressing full length ε-SG in bacteria was technically challenging due to the  
 
hydrophobic nature of  the transmembrane region, which tends to induce the formation of  
 
insoluble inclusion bodies when expressed in bacteria. GST fusion proteins of the  
 
cytosolic and extra-cellular domain of ε-SG were produced in BL21 Codon Plus E.coli  
 
and then affinity purified from the bacterial lysates using glutathione sepharose beads.  
 
During the protein purification procedure, it was found that GST-ε-SG-Cyt was  
 
expressed solubly in bacteria, while GST-ε-SG-ECD was expressed as insoluble  
 
inclusion bodies (data not shown). Hence, the cytosolic domain of ε-SG was chosen as  
 
the antigen of choice for antibody production. The GST moiety was cleaved off the GST- 
 
ε-SG-Cyt to prevent the production of contaminating anti-GST antibodies. The resulting  
 
rabbit anti-ε-SG-Cyt antibody produced was then characterized before being used as a  
 
tool for the detection of ε-SG in samples.  
 
3.1.1 Purification of ε-SG-GST fusion proteins - The first step for the production of  
 
recombinant protein entailed protein induction via addition of IPTG to cultures of BL21  
 
Codon Plus E.coli harboring plasmids pBH1 and 2, containing GST-ε-SG-Cyt and GST- 
 
ε-SG-ECD cDNAs, respectively. The Coomassie Blue staining of the PAGE gel for  
 
verifying optimal expression levels is shown in Figure 7. As shown in the figure, both  
 
GST- ε-SG Cyt and ECD could be highly expressed in E.coli (approximately 10µg/ml   
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bacterial culture of recombinant protein). GST- ε-SG-Cyt and GST- ε-SG-ECD migrate  
 




The next step involved affinity purification of the GST recombinant proteins from  
 
crude bacterial lysates using glutathione sepharose beads. Figure 8 shows the result of the  
 
affinity purification of GST-ε-SG-Cyt and GST-ε-SG-ECD. The amount of GST- ε-SG  
 
Cyt purified from soluble bacterial lysates was approximately 100 fold higher than that of  
 
GST- ε-SG-ECD. This was because most of the GST- ε-SG-Cyt was expressed solubly  
 
while the bulk of GST- ε-SG-ECD was expressed in insoluble inclusion bodies. A  
 
cysteine rich region is present in ε-SG-ECD, indicating the presence of disulphide bonds.  
 
The cytosolic environment of  E.coli is reducing and therefore does not favor disulphide  
 
bond formation (Hauke et al 1998). It can thus be hypothesized that ε-SG-ECD was  
 





To circumvent this putative problem, the Rosetta-gami E.coli was used to produce  
 
soluble GST-ε-SG-ECD. Mutations in both the thioredoxin reductase (trxB) and  
 
glutathione reductase (gor) genes are present in the Rosetta-gami strain of E.coli. This  
 
greatly enhances disulphide bond formation in its cytoplasm, thus increasing the  
 
probability of producing soluble GST-ε-SG-ECD. However, as the result in Figure 9  
 
shows, GST-ε-SG-ECD could not be produced solubly even using the Rosetta-gami  
 
E.coli and most of the protein was still expressed in the insoluble inclusion bodies (PSP).  
 
The “uninduced” sample was used as the negative control. From Figure 9, it can be seen  
 
that there was a band in the 56kDa region in the post sonication pellet sample (PSP),  
 
corresponding to the molecular weight (M.W.) of GST-ε-SG-ECD; while the 56kDa band  
 










Hence, from the above set of experiments, it was concluded that GST- ε-SG Cyt can be  
 
expressed solubly and affinity purified using glutathione beads, while GST- ε-SG ECD  
 
was expressed mainly as insoluble inclusion bodies.   
 
3.1.2 Isolation and purification of cytosolic domain of ε-SG - In order to produce  
 
antibodies against ε-SG, the cytosolic domain was cleaved from the GST moiety and  
 
served as an epitope for immunization of rabbits. Removal of the GST portion was done  
 
to minimize the production of antibodies to contaminating GST. In Annex A, the map of  
 
pGEX5X-1 vector shows that there is an FXa cleavage site between GST and the cloned  
 
gene of interest. FXa cleavage of ε-SG cytosolic domain from GST can thus be achieved  
 
using FXa protease, a process that needs to be optimized. The FXa cleavage optimization  
 
experiment is shown in Figure 10. A constant bed volume of GST-ε-SG-Cyt (10µl)  
 
 29 
coupled to glutathione sepharose beads was subjected to increasing units (U) of FXa  
 
enzyme. The beads were harvested by mild centrifugation (300 x g) and the material still  
 
bound to the beads or present in the supernatant analysed. If the cleavage was successful  
 
in a particular reaction, the cytosolic domain was expected to migrate as an 11kDa band  
 
in the supernatant, while only GST would be left coupled to the beads. As shown in  
 
Figure 10, there was a decrease in the amount of uncleaved GST- ε-SG Cyt (38kDa band)  
 
when more units of FXa were added. The purified and cleaved Cyt protein is present as a  
 
11kDa band, whereas the two additional bands of 34 and 29kDa appearing in the  
 
supernatant reflect FXa. GST, remaining bound to the beads, migrated as a band in the  
 
30kDa region. GST-ε-SG-Cyt coupled to beads which were not subjected to FXa  
 




From Figure 10, it could be determined that 1.5U of FXa enzyme was required for every  
 
10µl bed volume of GST-ε-SG-Cyt coupled to glutathione sepharose beads for an almost  
 
complete cleavage at R.T. Thus, these optimized conditions were extrapolated and used  
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in a scaled-up experiment to produce larger amounts of ε-SG-Cyt by cleavage of GST-ε- 
 
SG-Cyt (Figure 11). In order to remove FXa, which could interfere with specific antibody  
 
production, and obtain only the purified Cyt protein, the supernatant was incubated with  
 
Xarrest Agarose (FXa Cleavage Capture Kit, Novagen) for 15 mins at R.T. Xarrest  
 
agarose has affinity for FXa and will thus selectively remove the contaminating FXa  
 
from the supernatant. The efficiency of the removal was tested by analyzing an aliquot of  
 
the supernatant by SDS-PAGE and staining with Commassie. As shown in Figure 11,  
 
only the purified ε-SG-Cyt could be detected as the 11kDa band. No protein bands were  
 
found in the 29 and 34kDa region, indicating that FXa was efficiently removed. The  
 
resulting purified ε-SG-Cyt protein had a final concentration of 0.126µg/µl and 20ml  
 




3.1.3 Characterization of rabbit anti-ε-SG-Cytosolic domain antibodies - Upon the  
 
receipt of the rabbit anti-ε-SG-Cytosolic domain antibodies, the antisera were tested for  
 
specificity. Antisera from rabbit 5955 were chosen because preliminary results on  
 
Western blot showed that the antibody was more specific than those from rabbit 5956.  
 
The two criteria for characterization of antibody specificity were as follows. 
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3.1.3.1 Antibody characterization criteria 1: Rabbit 5955 anti-ε-SG-Cyt antibody  
 
could detect a specific signal in crude bacterial lysate expressing GST-ε-SG-Cyt but not  
 
in negative controls. From the Western blot shown in Figure 12, rabbit anti-ε-SG-Cyt  
 
specifically detected the cytosolic domain and not the ε-SG-ECD or the GST protein.  
 
This satisfies the first criteria for antibody specificity. 
 
 
   
3.1.3.2 Antibody characterization criteria 2:   To further analyze the specificity of the  
 
antibody, a competition assay was done. Figure 13 shows that increasing amounts of the  
 
specific antigen i.e. ε-SG-Cyt out-competed the signal for ε-SG in mouse brain lysates  
 
ran on Western blots; whereas increasing amounts of a protein that has no affinity to the  
 
antibody such as GST did not out-compete the signal. The pre-immune serum was also  
 
used as a negative control. The competition assay demonstrates that the antibody is  
 
specific and that in mouse brain lysates, it specifically detects two bands at 75kDa  
 
and 48kDa. The literature about ε-SG only reports the 48kDa protein, which corresponds  
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to the calculated molecular weight of ε-SG, but the larger 75kDa is not reported. Thus,  
 
our preliminary data indicates that a 75kDa form of ε-SG, probably carrying post- 
 




3.2 Detection of ε-SG in mouse and human tissues (brain) – The cytosolic domain of  
 
human ε-SG was used as epitope for the antibody production. Hence, to compare the  
 
specificity of the antibody between human and mouse, a Western blot with total protein  
 
samples of human and mouse brain run adjacent to each other was probed with the  
 
antibody.  The Western blot in Figure 14 indicates the presence of ε-SG in both human  
 
and mouse brain. There was a lower band below 48kDa present in the human but not in  
 
the mouse brain sample, indicating a possible alternative isoform of ε-SG in humans that  
 
can be detected by this antibody. Four splice variants of ε-SG transcripts have been  
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reported to exist in mouse brain. (Nishiyama et al 2004) Hence, it can be extrapolated  
 
from this preliminary data that isoforms of ε-SG may be detected in human brain. As  
 
observed earlier for mouse brain, a 75kDa protein was also detected in human brain  
 
samples. It can be speculated that the 75kDa protein may be a highly glycosylated form  
 
of ε-SG as ε-SG is known to be N-linked glycosylated in its ECD region. Alternatively,  
 
the antibody may cross react with a protein carrying homology to the ε-SG cytosolic  
 
domain. A BLAST search however reveals no other proteins in the brain carrying high  
 




3.3 Biochemical properties and presence of endogenous ε-SG in different cell lines-  
 
It was found that ε-SG was present in cell lines like 293T, which is derived from human  
 
kidney epithelial cells and Cos-1 cells, derived from fibroblastic Cercopithecus aethiops  
 
(African green monkey) kidney cells (Figure 15). ε-SG is a transmembrane protein. In  
 
order to study its biochemical properties, it needs to be solubilized. Hence, to determine  
 
its solubility, the detergent, polyoxyethylenesorbitan monolaurate (Tween 20) was used  
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to extract endogenously expressed ε-SG from tissue culture cells. If ε-SG present in the  
 
cells was solubilized by Tween 20, upon being subjected to detergent treatment and  
 
centrifuged, ε-SG would be found only in the supernatant and not the pellet. From Figure  
 
15, it can be observed that ε-SG was solubilized by 0.1% Tween 20. No ε-SG was  
 
detected in the pellet and ε-SG was present only in the supernatant. Moreover, there were  
 
different forms of ε-SG in the two different cell lines. Similar to brain lysates, ε-SG was  
 
present as 75kDa and 48kDa forms in Cos-1 cells, but there was an additional band of  
 




3.4 Identification of proteins that interact with ε-SG using a proteomics approach-  
 
The only known interactor of sarcoglycan to date is filamin 2. Muscle specific filamin 2  
 
(FLN2) has been shown to be associated with the intracellular domain of γ-sarcoglycan  
 
(Thompson T.G., et al 2000). In order to identify additional proteins interacting with the  
 
cytosolic domain of ε-SG, an approach using proteomics combined with mass  
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spectrometry was employed. 
 
3.4.1 Isolation of interacting proteins- A GST interaction assay was employed using  
 
GST-ε-SG-Cyt as bait. Mouse brain lysates were incubated with GST-ε-SG-Cyt. The  
 
interacting proteins were then resolved by SDS-PAGE and visualized using imidazole- 
 
sodium dodecyl sulphate-zinc reverse (negative) stain method. Approximately 12 protein  
 
bands of interest were excised and mass spectrometric analysis was done for protein  
 
identification (data not shown). Most of the bands identified from the mass spectrometric  
 
results were either redundant, unidentifiable proteins or background proteins like keratin.  
 
Only one protein which appeared as 42kDa showed promising result. The protein was  
 
identified as Erk2p. 
 
 
3.4.2 Identification of Erk2p as a putative ε-SG interacting protein- Mass  
 
spectrometry analysis revealed that Erk2p may associate with the cytosolic domain of ε- 
 
SG. For mass spectrometry analysis, the higher the expected (e)-value the higher is the  
 
probability of the identity of the indicated protein being accurate. A good e-value would  
 
be 4 and above. Mouse Erk2 had scored the highest e-value of 3.89e+004. The e- 
 
values are shown in Table 3 and human Erk2 showed up in the mass spectrometry result  
 
due to its high homology to mouse Erk2. The peptides detected by mass spectrometry are  
 





3.5 Verification of the interaction between ε-SG and Erk2p- In order to verify the  
 
possible interaction between ε-SG and Erk2p, three approaches were employed. The first  
 
was to establish their endogenous interaction in mouse brain lysates. This was done using  
 
GST pull down and IP experiments. The second assay was transfection of ε-SG  
 
constructs into mammalian tissue culture cells and then detecting interaction of the  
 
exogenously expressed ε-SG with endogenous Erk2p using IP. The third approach used  
 
was in vitro-transcription/translation of the two proteins and then detecting their  
 
interaction by GST pull down and IP assays. 
 
3.5.1 Interaction between ε-SG and endogneous Erk2p in soluble mouse brain 
 
lysates-   
 
3.5.1.1 GST interaction assay and verification by Western blot- To verify the  
 
association of Erk2p with the cytosolic domain of ε-SG, a GST interaction assay was  
 
performed using soluble mouse brain lysates. Antibodies against Erk2p were used for  
 
detection of Erk2p on the Western blot. The result shown in Figure 17 demonstrates that  
 
Erk2p associates with GST-ε-SG-Cyt. The presence of Erk2p was detected only when  
 
GST- ε-SG-Cyt was incubated with soluble mouse brain lysate. No Erk2p was detected  
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when GST only was used. The result from this GST interaction assay demonstrated  
 





3.5.1.2 Verification of interaction by co-IP- To further verify the interaction, a co-IP  
 
experiment was performed with soluble mouse brain lysates using different types of  
 
detergents (see materials and methods) to optimize the conditions for binding. Anti-Erk2p  
 
antibody was used in this IP to capture Erk2p from the lysates. A Western blot was  
 
probed for ε-SG using the Biogenes antibody to detect its binding with Erk2p. The results  
 
shown in Figure 18 indicate in vivo association of endogenous Erk2p with the 48kDa ε- 
 
SG. The experimental condition which showed a better IP result was 0.1% Tween-20  
 
PBS (Figure 18a), the same binding condition used in the GST pull down assay. Binding  
 
was also observed when the other detergents were used. No interaction was observed  
 
when non-specific mouse IgG was used as a negative control, thus demonstrating  
 
specificity of the interaction. The interaction with the 75kDa band was inconclusive and  
 







The co-IP was also performed the other way round, i.e., anti-ε-SG-Cyt antibody was used  
 
to capture ε-SG in the lysates and the binding detected with anti-Erk2p antibody on  
 
Western blot. Although an association between Erk2p and ε-SG could be detected, the  
 
results are not shown because of the  high background on the blot.       
 
3.5.2 Analysis of ε-SG constructs transfected into mammalian cells- Constructs of ε- 
 
SG, pBH3, 4, 5, 6, 7, 8 and 9 were designed to enable ε-SG to be expressed in  
 
mammalian cells for further analysis of the properties of the expressed protein. Upon  
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examination of the amino-acid sequence of the cytosolic domain of ε-SG, we discovered  
 
that it contains a putative ERK docking site or “D-site”. D-sites are found in MAPK  
 
kinases (MKKs or MEKs) and allow specific docking between MAPKs and their  
 
activating MEKs. Their consensus sequence is (K/R)2-3X1-6-(L/I)-X-(L/I) (Ho D.T et al  
 
2003); where K is lysine, R is arginine, X is any amino-acid, L denotes leucine and I  
 
denotes isoleucine. The D-site of the various MEKs compared to the D-site in the  
 




As shown in Figure 19, the consensus sequence fits the sequence found in the cytosolic  
 
domain of ε-SG. An alignment of rat, mouse and human amino-acid sequence of ε-SG is  
 
shown in Figure 20 (adapted from J. Xiao et al 2003) and shows that the D-site is  
 





3.5.2.1 Deletion constructs for the characterization of the D-site in the cytosolic  
 
domain of ε-SG- In order to characterize the role of the putative D-site of ε-SG in the  
 
interaction with Erk2p, epitope tagged ε-SG deletion constructs, pBH3, 4 and 5 were  
 
designed. As shown in Figure 20, the N-terminus of ε-SG contains a 46 amino- acid  
 
hydrophobic signal sequence followed by a 270 amino-acid (sequence 47-316)  
 
extracellular domain underlined as indicated. The hydrophobic transmembrane (TM)  
 
region is the non-underlined region from amino-acids 317-339 (see Discussion). The  
 
deletion constructs that were constructed had a murine Ig Kappa (Igκ) signal sequence  
 
placed before the N-terminal FLAG and the FLAG epitope fused in frame with the N- 
 
terminus ECD of ε-SG beginning with the 49th amino-acid, asparagine (N). This was  
 
done to replace the endogenous signal sequence. The Igκ secretory signal sequence  
 
directs translocation of the protein of interest (Coloma et al 1992) across the ER  
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membrane. However, since there is a membrane anchoring sequence in ε-SG, the protein  
 
will be inserted into the plasma membrane instead, reflecting the putative native  
 
membrane orientation of ε-SG. The Igκ signal peptide will get cleaved off in the process  
 
leaving the FLAG epitope tagged to ε-SG. Schematic depictions of the different deletion  
 
constructs are shown in Figure 5, section 2.3. 
 
The rationale behind the different constructs is elaborated in the Discussion and can be  
 
summarized as follows. pBH3 has the full length ε-SG, while pBH4 has the cytosolic  
 
domain truncated up to and including the D-site. pBH5 is a construct with all of the  
 
cytosolic domain truncated, leaving only the TM region and a few charged amino acids  
 
just after the TM region (not shown in figure 5) so as to stabilize the protein during  
 
membrane insertion. The constructs were transfected into mammalian cell lines and then  
 
co-IP was carried out to see if Erk2p interacted with the cytosolic domain of ε-SG.  
 
Hypothetically, if the D-site is responsible for the interaction of Erk2p with the cytosolic  
 
domain, then the different immunoprecipitated ε-SG, pBH3 and pBH4 will show Erk2p  
 
interaction upon co-IP while pBH5 will show a negative result because the cytosolic  
 
domain is completely absent. However, before the co-IP was done, a Western blot of total  
 
cell lysates transfected with the abovementioned constructs was carried out to check for  
 
optimal expression levels of the FLAG tagged ε-SGs.  
 
3.5.2.2 Western blot of deletion constructs transfected into 293T cells- As can be seen  
 
in Figure 21, even in 293T cells, a highly transfectable cell line, ε-SG was not expressed  
 
very well. ε-SG C-terminal ∆ and ε-SG D-site constructs were expressed at low levels in  
 
the transfected cells. Presence of ε-SG full length could not be detected as shown in the  
 
Western blot. No difference can be found in the banding profile of the ε-SG full length  
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lane compared to the pcDNA3 control lane. A FLAG-ZO2 construct was used  
 
as a positive control and the good expression of FLAG-ZO2 showed that the transfection  
 




3.5.2.3 IP from transfected Cos-1 cell lysates- To rule out that the problem of  
 
expressing ε-SG was a cell-type specific issue, Cos-1 cells were also transfected using the  
 
abovementioned deletion constructs. A Western blot was carried out to check for  
 
expression levels, but  the constructs were just as poorly expressed, if at all, in Cos-1  
 
cells (results not shown).  An IP experiment using mouse anti-FLAG M2 antibody  
 
coupled to agarose beads was performed on the Cos-1 lysates nonetheless. This  
 
experiment was done in the hope that the IP would concentrate the weakly expressed  
 






From the result, it can be deduced that the IP concentrated the deletion constructs to some  
 
extent, considering the fact that they did not show up at all on Western blots when  
 
transfected whole cell lysates were loaded. However, FLAG-ε-SG full length was the  
 
most weakly expressed amongst the different constructs as shown in the last lane of the  
 
blot. The bands of ~75kDa  would be consistent with the higher mass form of  
 
endogenous ε-SG detected in human and mouse brain samples.  
 
In conclusion, expressing FLAG-ε-SG deletion constructs in mammalian cell lines  
 
proved to be a challenging task. It was thought that the N-terminal FLAG epitope was  
 
causing disruption of ε-SG gene expression in pBH3, 4 and 5. Moreover, for the deletion  
 
constructs, the N-terminal hydrophobic signal sequences of ε-SG (its first 46 amino-acids  
 
indicated in Figure 20) were excluded and the Kozak sequence included in the constructs  
 
were not from genomic sequences upstream of ε-SG gene. Hence, the next attempt was to  
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generate constructs pBH6 and 7, with hemagglutinin (HA) tagged to the C-terminus  
 
of ε-SG, making sure to include the signal peptide and some genomic sequences  
 
upstream of ε-SG, hypothesized to be its endogenous Kozak sequence (see Discussion). 
 
3.5.2.4 ε-SG constructs with C-terminal HA tag, endogenous signal peptide and  
 
either the first or the first and second initiation methionine - The N-terminus of ε-SG  
 
contains a 46-amino acid signal peptide sequence followed by an extracellular domain  
 
(Figure 20). There are two methionines in the signal peptide sequence (position 1 and 25,  
 
respectively). To date, there are no published reports as to the translation start site used in  
 
ε-SG. In order to elucidate from which of the two methionines translation of ε-SG starts,  
 
constructs were made that include either both methionines or only the first or second one.  
 
This lead to the creation of constructs pBH6, 7, 8 and 9 (Figure 6, section 2.4) which  
 
were transfected into Cos-1 and 293T cells. The star in Figure 6 represents the first ATG  
 
of ε-SG cDNA mutated to TTG to inactivate the initiation ATG. pBH6 and 7 contain  
 
cDNA sequences 22 bases upstream from the first ATG of the ε-SG cDNA. pBH8 and 9  
 
contains Kozak sequences which had been well characterized (Kozak M. et al 1987).  
 
pBH 6 and 7 both contain a C-terminal HA epitope tag while pBH 8 and 9 both contain  
 
an N-terminal FLAG tag.  
 
3.5.2.5 Transfection of pBH6, 7, 8 and 9 into Cos-1 and 293T- Cells transfected with  
 
pBH 6, 7, 8 and 9 failed to expressed the tagged ESG proteins as assessed by Western  
 
blot (data not shown). Therefore, we proceeded to analyze if the proteins could be  
 
expressed in vitro using coupled in vitro transcription/translation.   
 
3.5.3 In vitro-transcription/translation of ε-SG Constructs pBH6, 7, 8 and 9- In vitro- 
 
transcription/translation of the constructs were carried out in the hope that it would be  
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possible to obtain more ε-SG protein to perform the GST pull down and IP assays  to  
 
verify if the interaction of the two proteins is direct or indirect. An initial experiment was  
 
performed by using TnT Quick Coupled Transcription/translation system alone without  
 
the addition of canine pancreatic microsomal membranes (CMM). However, the reactions  
 
showed no expression of the proteins however (data not shown). Since ε-SG is a  
 
transmembrane protein, CMM was added to the in vitro-transcription/translation mixture.  
 
However, the amounts added to the reaction must first be determined empirically, hence,  
 
a titration experiment was first performed as described in the next section. GST pull  
 
down and IP experiments were then done using the in vitro translated products.  
 
3.5.3.1 Optimization of in vitro-transcription/translation of ε-SG constructs using  
 
CMM- To determine optimal amounts of CMM, increasing amounts of CMM were  
 
added to the in vitro-transcription/translation reactions for the various ε-SG constructs.  
 
Western blots were then done to detect the synthesized proteins (Figure 23). As can be  
 
seen, increasing amounts of CMM increased the amount of ε-SG protein produced. The  
 
optimized amount of CMM to be added to the mixture was therefore determined to be  
 
1.8µl per 25µl reaction. The bands in all blots are specific because the Erk2p epitope  
 
tagged protein was detected and no bands are detected in the pcDNA3 vector negative  
 
control lane. The molecular weights of ε-SG in all cases are more than 50kDa. Even with  
 
the epitope tags, the calculated molecular weight of ε-SG is around 50kDa. Thus, the  
 
molecular weight increase could be attributed to post-translational modification by the  
 
addition of CMM and is in line with the higher MW band observed in brain lysates. Of all  
 
the constructs, the best expressed was pBH6, (Figure 23a, pBH6), while the least well  
 





In vitro-transcription/translation of the deletion constructs pBH3, 4 and 5 was also  
 
performed but they were not successfully expressed in the system (data not shown). Since  
 
the in vitro-translated products of Erk2 and ε-SG were now available, GST interaction  
 
assay and immunoprecipitation experiments were be performed to study the interaction  
 
between these two proteins.   
 
3.5.3.2 GST interaction assay between the cytosolic domain of ε-SG and in vitro- 
 
translated Erk2-HA- To verify if the interaction of GST-ε-SG-Cyt and Erk2p is direct, a  
 
GST interaction assay was performed between the bacterially produced GST-ε-SG-Cyt  
 
and the in vitro-translated Erk2-HA. In vitro-translated Erk2-HA did not associate with  
 
GST-ε-SG-Cyt (Figure 24). This is in contrast with the GST interaction assay performed  
 
using soluble mouse brain lysates, indicating that the interaction between the two proteins  
 
may require posttranslational modification or, alternatively, may not be direct. IP  
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experiment using the full length in vitro-translated ε-SG and Erk2-FLAG was thus  
 





3.5.3.3 IP of in vitro-translated full length ε-SG-HA and Erk2-FLAG- It was  
 
suspected that the interaction between Erk2 and ε-SG is not a direct one or may require  
 
posttranslational modifications on Erk2 and/or ESG because no binding could be detected  
 
between GST-ε-SG-Cyt and in vitro-translated Erk2-HA. Thus, soluble mouse brain  
 
lysates were added to the IP mixture containing in vitro-translated full length ε-SG-HA  
 
and Erk2-FLAG to provide additional components for the binding. The co-IP experiment  
 
of in vitro-translated constructs also failed to show an association between Erk2 and ε-SG  
 
(Figure 25a). The M2 mouse anti-FLAG antibodies coupled to beads did IP the FLAG  
 
tagged proteins (Figure 25b), providing a positive control for the experiment. Thus,  
 
factors mediating either posttranslational modifications of Erk2 and/or ε-SG, or  
 
components required for an indirect interaction between the two proteins, cannot be  
 































   
The aims of this project were two-fold: First, to generate and characterize antibodies  
 
against ε-SG and second, to identify and verify possible interactors for the cytosolic  
 
domain of ε-SG. The experimental strategies employed consisted of (1) cloning the  
 
cDNA of ε-SG, (2) identifying the putative interactor(s) for the cytosolic domain of ε-SG  
 
using a proteomics/mass spectrometric approach and (3) verifying the interaction in vitro  
 
and in vivo using pull-down and co-IP experiments.  
   
  Multiple bands were detected by the antibody produced against the cytosolic domain of  
 
ε-SG. Two bands of 75 and 48kDa were detected in mouse brain; while three bands were  
 
detected in human brain, i.e., 75, 48 and a lower 47kDa band. It is difficult to speculate if  
 
the 75kDa band corresponds to the glycosylated form of ε-SG. To test this possibility, the  
 
protein would need to be treated with N-glycosidase to observe if the 75kDa band is  
 
cleaved to a lower molecular weight. Interestingly, however, the higher MW band was  
 
generated if the cDNA for ε-SG was in vitro translated in the presence of CMM, which  
 
are known to mediate posttranslational modifications such as glycosylation. Nishiyama et  
 
al (2004) reported that two splice variants of ε-SG, a 49kDa and a 47kDa isoforms, are  
 
found in mouse brain. In that report, the antibody employed was produced using the C- 
 
terminal region of mouse ε-SG. Here, we produced an antibody against the C-terminal of  
 
ε-SG from sequences derived from the human protein. We detected a 48kDa and a lower  
 
47kDa band in human brain but the antibody only detected a 48kDa band in mouse brain.  
 
The higher 75kDa band detected in both mouse and human brain samples was not  
 
reported by Nishiyama et al. From the Western blot data shown in Figure 9 and the  
 
Nishiyama paper, it is reasonable to hypothesize that more than one ε-SG splice variants,  
 
 50 
(i.e. the 47kDa and 48kDa forms), is also present in the human brain. Based on the  
 
competition assays, the antibody generated in rabbits against the cytosolic tail of human  
 
ε-SG was specific for ε-SG. However, other proteins with a high degree of homology to  
 
ε-SG and a common epitope could be recognized by the antibody. The only protein which  
 
has a high degree of homology to ε-SG is α-SG, (adhalin) (Ettinger A.J. et al 1997,  
 
McNally E.M. et al 1998), however, α-SG does not appear to be present in the brain. The  
 
generation of a high MW protein by in vitro transcription/translation of the ε-SG cDNA  
 




  Two approaches were initially explored to identify interacting partners of the cytosolic  
 
domain of ε-SG: a yeast two-hybrid screen and proteomics. The proteomics approach was  
 
followed up because obstacles were encountered during the two the hybrid screening. At  
 
the final stages of the yeast two-hybrid screening, too many colonies appeared as putative  
 
positive interactors for the cytosolic tail of ε-SG. Identification of interactors using  
 
proteomics has its own pitfalls. First, GST pull down experiments only represent in vitro  
 
settings in which the two proteins are associated. Upon identification of interacting  
 
partners by proteomics/mass spectrometric approaches, the in vivo association needs to be  
 
verified within the cellular context. This could be done by co-immunoprecipitation assays.  
 
Second, during a GST pull down, proteins that are not normally associated in the cell  
 
may be brought together when the cells are lysed. Moreover, for a GST interaction assay,  
 
the equilibrium constant of the reaction are shifted in favor of the interaction because of  
 
the massive amount of recombinant protein used in the assay (in the µg range). This is not  
 
representative of what is occurring in the in vivo context within the cell. Nevertheless,  
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GST pull down assays were the method of choice for the identification of interacting  
 
partner of the cytosolic tail of ε-SG because of the availability of the bacterially produced  
 
recombinant GST-ε-SG-Cyt as well as mouse brain lysates. The only know ε-sarcoglycan  
 
interactor to date is Filamin 2 (FLN2) (Thompson T.G. et al 2000) a muscle-specific  
 
sarcoglycan interacting protein. FLN2 was reported to bind the cytosolic domain of γ and  
 
δ sarcoglycan but not α or β sarcoglycan. No interactor for the cytosolic domain of ε-SG  
 
has yet been published. Here, through GST pull down assays and proteomics/mass  
 
spectrometric approaches, we identified Erk2p as a putative interactor for the cytosolic  
 
domain of ε-SG. This result was corroborated with the positive interaction between the  
 
two endogenous proteins as shown by co-IP from mouse brain lysates. However, contrary  
 
to the data presented by the GST interaction assay and co-IP experiments, an interaction  
 
between Erk2p and ε-SG could not be reproduced in in vitro translation systems. One  
 
possible reason could be the association between the two proteins required certain post- 
 
translational modifications like phosphorylation which do not occur when the proteins are  
 
produced in vitro; while an alternative possibility is that the interaction is indirect and  
 
requires bridging proteins. 
 
  Expression of different ε-SG constructs in cell lines like 293T and Cos 1 cells proved to  
 
be a challenge. Igκ FLAG ε-SG deletion constructs (i.e. plasmids pBH 3, 4 and 5) were  
 
designed to characterize the putative D-site identified by homology analysis in the  
 
cytosolic domain of ε-SG. Since the cells failed to express the constructs, downstream  
 
experiments like IP could not be performed. Entirely newly constructs (i.e. pBH 6, 7, 8  
 
and 9) where the first and/or second methionine were present in the coding region of the  
 
ε-SG sequence were designed. There are 2 two putative initiation methionines, at position  
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1 and 25 of the ε-SG amino acid sequence and it is not clear if there is a cleaved signal  
 
sequence, although the sequence has been claimed to be a putative signal sequence in one  
 
report (Xiao. J. et al 2003). A transmembrane prediction program, Transmembrane  
 
Protein Labeling Environment, TRAMPLE, (Fariselli. P. et al 2005) analysis of the  
 
amino acid sequence of ε-SG, shows that ε-SG may contain two transmembrane regions.  
 










Both these algorithms predict that ε-SG contains two transmembrane domains. The  
 
HTMR neural-network based predictor exploits evolutionary information derived from  
 
PSI-BLAST on the non-redundant dataset of protein sequences; while PSI KD is based  
 
on the classical Kyte-Doolittle’s protein hydrophobicity plot and take as input either  
 
evolutionary information in the form of sequence profiles or the single sequence (Fariselli.  
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P. et al 2005). Another program, SignalP 3.0 (Bendtsen J.D. et al 2004), which predicts  
 
the presence or absence of signal peptide, was also used. SignalP 3.0 predicts the  
 
presence and location of signal peptide cleavage sites in amino acid sequences from  
 
different organisms, including eukaryotes. The method incorporates a prediction of  
 
cleavage sites and a signal peptide/non-signal peptide prediction based on a combination  
 
of several artificial neural networks and hidden Markov models. SignalP-HMM  
 
prediction program calculates the probability that the first 46 amino acids of ε-SG does  
 
not contain a signal peptide but a signal anchor (Figure 28). Its low C and Y score, <0.5  
 
and its low signal peptide probability, <0.5 indicates that a signal peptide is absent from  
 
ε-SG. Its signal anchor probability score, however is high (>0.5). This is consistent with  
 
the TRAMPLE data, which predicts that a signal peptide is absent from the first 46 amino  
 
acids of ε-SG (data not shown). This contradiction to an earlier report that a signal  
 
peptide was present in ε-SG (Xiao J. et al 2003) was because the authors used an earlier  
 











   It must, however, be taken into consideration that the TRAMPLE data only represents a  
 
computer simulation. It could also be argued that the first transmembrane domain (amino  
 
acids 28-43), may be too short to span the lipid bilayer of the plasma membrane; with the  
 
segment 314-340 being more likely to be a transmembrane region. Thus, based on the  
 
data from the above computational analysis, pBH 6, 7, 8 and 9 were designed. pBH6  
 
contains both the first and second methionines of ε-SG, while pBH7 had the first  
 
methionine mutated to observe if it is essential for the initiation of expression of ε-SG.  
 
pBH8 contains ε-SG sequences starting after the first methionine, while pBH9 contains  
 
sequences starting after the second methionine. However, these constructs were not 
 
expressed in 293T or Cos-1 cells. One hypothesis might be that expression of ε-SG in  
 
cells could be subjected to tight regulation and its mRNA may be  destroyed before being  
 
successfully translated. It is noteworthy in this regard that there are no publications to  
 
date showing expression of ε-SG in transfected 293T and/or Cos-1 cell lines. Another  
 
possibility is that expression of ε-SG requires additional components to stabilize the  
 
protein in the ER and prevent its premature degradation. It could thus be deduced that the  
 
cell lines 293T and Cos 1 are unsuitable for successful expression of ε-SG and a neuronal  
 
cell line may need to be employed instead. More success was obtained when pBH6, 7, 8  
 
and 9 were subjected to in vitro transcription/translation.  
 
  If a D-site is indeed present in the cytosolic domain of ε-SG, one way of characterizing  
 
it would be to examine if the site is prone to cleavage by anthrax lethal factor protease.  
 
All proven MAPK-docking sites found in the N termini of mammalian MKKs are also  
 
substrates for anthrax lethal factor cleavage (Ho. D.T et al 2003). Purified protein from  
 
the in vitro transcription/translation system could be used for this purpose.  
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  Interesting with respect to the possible interaction between ε-SG and Erk2 uncovered in  
 
our work is an earlier report showing a relationship between sarcoglycan and MAP  
 
kinase signaling (Woodman S.E. et al 2002). This paper showed that in Cav-3 knock-out  
 
mice, a marker of the dystroglycan complex, α-SG, was specifically excluded from lipid  
 
raft domains and that the  p42/44 MAPK cascade was hyperactivated. MAPK pathway  
 
activation was also observed in γ-SG deficient cells (Griffin M.A et al 2005), further  
 
implicating sarcoglycans in MAP kinase signaling. The more recent paper also provides  
 
evidence that the sarcoglycans are involved in the transduction of mechanical information  
 
in the skeletal muscle via the MAP kinase pathway, potentially unique from the entire  
 
DGC (Barton et al 2006).  
 
  The data presented in this thesis suggests a possible interaction between the cytosolic  
 
domain of ε-SG and Erk2p in murine brain. Mutations resulting in loss of function of ε- 
 
SG leads to MDS. It can thus be hypothesized that this loss results in subtle changes in  
 
the neuronal architecture that give rise to the abnormal phenotypes, e.g. abnormal  
 
movements and psychiatric disturbances like panic attacks and obsessive compulsive  
 
disorder, observed in patients with mutations in the ε-SG gene (Zimprich et al 2001) and  
 
that aberrant MAP kinase signaling may play an underlying role in the molecular  
 
pathogenesis of MDS.  
 
  Indeed, in another neuropathological condition, schizophrenia, it was found that levels  
 
of both the active and inactive forms of Erk2 were either elevated or decreased in  
 
different regions of postmortem human brain samples as compared to normal control  
 
subjects (Kyosseva et al 1999). Similarly, Erk2 phosphorylation was shown to be more  
 
robust in muscles of γ-SG knock-out mice as compared to controls when the muscles  
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were subjected to eccentric contractions (Barton et al 2006). 
 
 In conclusion, while a role of ε-SG in the regulation of signal transduction via Erk2  
 
remains to be established, the data presented in this thesis suggests that Erk2 associates  
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                                     Table 1: Plasmids used in this study 
Plasmid                      Description                                                                                   Source 
         pBH 1            pGEX5X-1 with ε-SG cytosolic domain (encoding pGSTε-SG-Cyt)           This study  
 
pBH 2            pGEX5X-1 with ε-SG extra-cellular domain (encoding pGSTε-SG-ECD)  This study                                          
 
pBH 3            pcDNA3 N-terminal Igκ FLAG ε-SG Full Length                                        This study 
 
pBH 4            pcDNA3 N-terminal Igκ FLAG ε-SG D-site                                                 This study 
 
pBH 5            pcDNA3 N-terminal Igκ FLAG ε-SG C-terminal ∆(delete)                           This study 
 
pBH 6            pcDNA3 Endogenous Kozak 1st ATG C-terminal HA Full length ε-SG       This study 
 
pBH 7            pcDNA3 Endogenous Kozak 1st ATG mutated C-terminal HA 
                           Full length ε-SG                                                                                              This study 
 
pBH 8         pcDNA3 Established Kozak N-terminal FLAG 1st ATG  Full length ε-SG     This study                                
 
pBH 9         pcDNA3  Established Kozak N-terminal FLAG 2nd ATG Full length ε-SG     This study 
 
pCMV-            Full length ε-SG from Placenta Cot 25-Normalized  
SPORT6            EST clone CS0DI008YP01                                                                           Invitrogen 
 
pXJ40 
Erk2-FLAG    N-terminal FLAG Erk2 from mouse brain                                                  Ben McCaw 
 
pXJ40 
Erk2-HA         N-terminal HA Erk2 from mouse brain                                                      Ben McCaw 
 
pcDNA3 
ZO2-FLAG     N-terminal FLAG-ZO2 Full Length                                                           D.C.Y. Phua 
 
pcDNA3         Mammalian expression vector                                                                     Invitrogen 
 
pGBKT7        Yeast-two-hybrid DNA-BD vector                                                              Clontech 
 
pGEX5X-1     GST fusion vector                                                                                       Amersham/Pharmacia 
                                                                                                                                                        Biotech AB  
 
 
                                                                                                                                                          
                                                                                                              





                                                 Table 2: Primers used in this study                                                              
Primer                                 Description                                                  Sequence (5’-3’)                                                                           
P1       ε-SG forward sequencing primer position     1-21       of gene   atgcaattgccccggtggtgg 
P2       ε-SG forward sequencing primer position   406-429   of gene   aggcgcacctttgagactgcaag 
P3       ε-SG forward sequencing primer position   628-649   of gene   agggtgccacttcccattaatg  
P4       ε-SG forward sequencing primer position   844-868   of gene   gtgtccacctatcaggaagtgattc 
P5       ε-SG reverse  sequencing primer position 1282-1258 of gene   gggaatctgagtctgatgtggcaag 
P6       ε-SG reverse  sequencing primer position 1039-1018 of gene   cacgccttcccgtcggcagcacatgat 
P7       ε-SG reverse  sequencing primer position   693-664   of gene   cgggacatctgcaccaaccatgacata- 
                                                                                                                -aac 
P8       ε-SG reverse  sequencing primer position   411-384   of gene   gcgcctgttgtaggcagttatctcaatg 
P9       ε-SG reverse primer for cloning with stop and XhoI site           ggagaaaccgctaactcgagtcaggg- 
           position 1314 (end cytosolic) of gene                                         -ataccatttacctgtagt  
P10     ε-SG reverse primer for cloning with stop and BamHI site       ggagaaaccgctaaggatccctaggg- 
           position 1314 (end cytosolic) of gene                                         -ataccatttacctgtagtctg 
P11     ε-SG forward primer for cloning cytosolic region of gene         aatcgccaaagaggaattcatgtgctg- 
           position 1015 with EcoRI site                                                     -ccgacgggaaggc 
P12     ε-SG forward primer for cloning extra-cellular domain             aatcgccaaagagggatccccaatgta-  
           (ECD)of gene position 145 with BamHI site                              -tacccatcagcaggtgtc 
P13     ε-SG reverse primer for cloning ECD of                                    ggagaaaccgctaactcgagtcaatcc- 
           gene position 943 with XhoI site                                                -gtgtaatagtctctgcttttcaa 
P14     BamHI IgKappa with kozak forward primer                              acgctaaggatccggctagccaccatg- 
            -gagacagacacactcctgctatgg 
P15     ε-SG forward primer for cloning ECD of gene                           aatgtatacccatcagcaggtgtcctctt- 
            position 145                                                                                 -tgttcatg 
P16     ε-SG reverse primer with XhoI site for cloning                          ccgctaactcgagtcacacgccttcccg- 
            gene up to transmembrane region position 1039                        -tcggcagcacat 
P17     ε-SG reverse primer with XhoI site for cloning                          ccgctaactcgagtcaaatagcactgtg- 
           gene up to D-Box region position 1092                                       -atggaccagttggatgtctggtgtttg 
P18     ε-SG reverse primer with XhoI site for cloning                          ccgctaactcgagtcagggataccattt- 
           full length gene position 1314                                                     -acctgtagtctgctgttggg 
P19     ε-SG reverse primer creating an N-terminal FLAG                    catgaacaaagaggacacctgctgatg- 
            tag to the ECD domain position 145                                          -ggtatacattcttgtcatcgtcatctttgta- 
             -gtc 
P20     ε-SG forward primer with -22 upstream endogenous                  acgctaaggatccggacggcctagcca- 
           Kozak, 1st ATG and BamHI site                                                  -ggccaagaatgcaattgccccggtggt- 
                                              -gggagc 
P21     ε-SG forward primer with -22 upstream endogenous                  acgctaaggatccggacggcctagcca- 
           Kozak 1st ATG mutated to TTG and BamHI site                         -ggccaagattgcaattgccccggtggt- 
                                                                                                                 -gggagc 
P22     ε-SG reverse primer with XhoI site and C-terminal HA tag       ccgctaactcgagtcaagcgtaatctgg- 
           for cloning full length gene position 1314                                   -aacatcgtatgggtagcagggatacc- 





                                       Table 2: Primers used in this study (cont’d)                                                             
Primer                               Description                                           Sequence (5’-3’)                                                                     
P23    ε-SG forward primer containing established Kozak and    acgctaaggatccggaagtgaccatggactac- 
          N-terminal FLAG before 1st ATG                                    -aaagatgacgatgacaagcaattgccccggt- 
            -ggtgggagc 
P24   ε-SG forward primer containing established Kozak and    acgctaaggatccggaagtgaccatggactac- 
         N-terminal FLAG before 2nd ATG                                   -aaagatgacgatgacaagagccccgcgaccac- 
                                                                                                   -tggcacattcttg 









                    Table 3: e-values of Proteins Detected by MALDI-TOF Mass Spectrometry 
 
e-value                                                   Species            NCBI-accession     Protein Identity 
                                                                                            Number                     
1.86e+005 9/50 (18%) 40420.9 / 6.67   Homo sapiens    23879           40kDa protein kinase 
 
1.81e+005 9/50 (18%) 41389.9 / 6.50   Homo sapiens    20986531     Mitogen-activated protein kinase 1  
                                                                                                               (Extracellula signal-regulated kinase 2)  
                                                                                                               (ERK-2) 
                                                                                                               (Mitogen-activated protein kinase 2)  
                                                                                                               (MAP kinase 2) (MAPK 2)  
                                                                                                                (p42-MAPK) (ERT1)  
 
1.81e+005 9/50 (18%) 41404.0 / 6.67   Homo sapiens     20986529     Mitogen-activated protein kinase 1 
                                                                                                                (Protein tyrosine kinase ERK2) 
                                                                                                             (Extracellular signal-regulated kinase 2) 
                                                                                                                (Mitogen-activated protein kinase 2)  
 
4.27e+004 9/50 (18%) 41361.9 / 6.36  Homo sapiens     23881           41kD protein kinase  
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